Advisor Group’s Regulus Therapeutics RGLS Stock Holding History

Advisor Group’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2	Closed	–	–	4778
2016 Q4	$0	Hold	2	–	–	﹤0.01%	4598
2016 Q3	$1K	Hold	2	–	–	﹤0.01%	4343
2016 Q2	$0	Buy	+2	New	+$1.43K	﹤0.01%	4480

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisor Group's RGLS Position: Q1 2017 in Review

Advisor Group sold out of Regulus Therapeutics (RGLS) in Q1 2017, closing a stake of 2 shares.

Advisor Group first reported a position in RGLS in Q2 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 58 funds tracked by Wall St. Rank hold RGLS as of Q1 2017.

Advisor Group reported no remaining Regulus Therapeutics position as of Q1 2017 after selling out during the quarter.
Advisor Group sold 2 Regulus Therapeutics shares in Q1 2017.
Advisor Group first reported a position in Regulus Therapeutics in Q2 2016 and held it in 3 quarters.
Advisor Group's Regulus Therapeutics position peaked at $1K in Q3 2016.
58 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2017.

Based on Advisor Group's 13F filing for Q1 2017, filed 15 May 2017.